Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 1/20 | 0.33 |
| ▸ | MAOB | P27338 | 1/20 | 0.33 |
| ▸ | TLR4 | O00206 | 1/20 | 0.32 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13635336 | 0.69 | GPR119 (0.35) | TLR4 | |
| SCHEMBL17430790 | 0.69 | CYP2C9 (0.42) | TLR4CYP2C9 | |
| SCHEMBL12433696 | 0.69 | HRH3 (0.33) | TLR4 | |
| SCHEMBL4388855 | 0.68 | TLR4 (0.32) | TLR4CYP2C9 | |
| SCHEMBL4936791 | 0.68 | CYP1B1 (0.43) | CYP2C9 | |
| SCHEMBL8737129 | 0.67 | CYP2C9 (0.43) | TLR4CYP2C9 | |
| SCHEMBL7569241 | 0.67 | CYP2C9 (0.43) | TLR4CYP2C9 | |
| SCHEMBL2884363 | 0.67 | CYP2C9 (0.43) | TLR4CYP2C9 | |
| SCHEMBL3437358 | 0.67 | CYP2C9 (0.43) | TLR4CYP2C9 | |
| SCHEMBL11132031 | 0.67 | OPRL1 (0.39) | TLR4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1409441-B1 | INDANE COMPOUNDS WITH NEGATIVE DIELECTRIC ANISOTROPY | MERCK PATENT GMBH (DE) | 2009-11-18 | — | — | EP | disclosed |
| EP-1409441-B1 | INDANE COMPOUNDS WITH NEGATIVE DIELECTRIC ANISOTROPY | MERCK PATENT GMBH (DE) | 2009-11-18 | — | — | EP | disclosed |
| US-7122228-B2 | Transistros; liquid crystals display; electrooptics | MERCK PATENT GMBH (DE) | 2006-10-17 | — | — | US | disclosed |
| US-20040171866-A1 | Transistros; liquid crystals display; electrooptics | MERCK PATENTGESELLSCHAFT (DE) | 2004-09-02 | — | — | US | disclosed |
| EP-1409441-A1 | INDANE COMPOUNDS WITH NEGATIVE DIELECTRIC ANISOTROPY | MERCK PATENT GmbH (DE) | 2004-04-21 | — | — | EP | disclosed |
| WO-2003010120-A1 | INDANE COMPOUNDS WITH NEGATIVE DIELECTRIC ANISOTROPY | MERCK PATENT GMBH (DE) | 2003-02-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040171866-A1 | Transistros; liquid crystals display; electrooptics | VCL, RIF1, IPO11 | MAOA 1975/4885MAOB 2061/4885TLR4 2032/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.